Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Netweb Technologies India Ltd, Globus Spirits Ltd, VST Industries Ltd and Jaiprakash Power Ventures Ltd are among the other gainers in the BSE's 'A' group today, 11 July 2025.
Glenmark Pharmaceuticals Ltd spiked 15.00% to Rs 2190.9 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 1.04 lakh shares were traded on the counter so far as against the average daily volumes of 21923 shares in the past one month.
Netweb Technologies India Ltd surged 5.47% to Rs 1912.4. The stock was the second biggest gainer in 'A' group. On the BSE, 1.02 lakh shares were traded on the counter so far as against the average daily volumes of 21540 shares in the past one month.
Globus Spirits Ltd soared 5.30% to Rs 1011.55. The stock was the third biggest gainer in 'A' group. On the BSE, 30438 shares were traded on the counter so far as against the average daily volumes of 5407 shares in the past one month.
VST Industries Ltd gained 5.30% to Rs 295.85. The stock was the fourth biggest gainer in 'A' group. On the BSE, 57356 shares were traded on the counter so far as against the average daily volumes of 52831 shares in the past one month.
Jaiprakash Power Ventures Ltd exploded 5.13% to Rs 24.2. The stock was the fifth biggest gainer in 'A' group. On the BSE, 316.68 lakh shares were traded on the counter so far as against the average daily volumes of 197.32 lakh shares in the past one month.
Under the terms of the agreement, IGI will collaborate with AbbVie to develop, manufacture, and commercialize ISB 2001, a first-in-class trispecific T-cell engager designed to treat multiple myeloma. AbbVie will handle development and commercialization in North America, Europe, Japan, and Greater China. Glenmark Pharmaceuticals will take charge of manufacturing and marketing the therapy in Emerging Markets, including Asia (excluding key developed markets), Latin America, the Russia/CIS region, the Middle East, Africa, Australia, New Zealand, and South Korea.
ISB 2001, currently in Phase 1 clinical development, targets BCMA and CD38 on myeloma cells and CD3 on T cells. Developed using IGI's proprietary BEAT protein platform, the asset is engineered to enhance efficacy even at low antigen expression levels while aiming to improve safety over traditional bispecific antibodies.
Data presented at the 2025 ASCO Annual Meeting showed promising results: a 79% overall response rate and 30% complete/stringent complete response in a heavily pretreated patient population. The therapy has also received Orphan Drug Designation (July 2023) and Fast Track Designation (May 2025) from the U.S. FDA for relapsed/refractory multiple myeloma.
With this landmark deal, Glenmark is poised to strengthen its footprint in the global oncology market while expanding patient access to next-gen immunotherapies across high-need regions.
'Our collaboration with AbbVie and Glenmark reflects IGI's mission to accelerate access to transformative multispecifics for patients worldwide,' said Cyril Konto, M.D., President, Executive Director and CEO of IGI. 'AbbVie's reach in major markets combined with Glenmark's commercial strength in Emerging Markets, creates complementary access pathways for ISB 2001, a trispecific T-cell engager with promising potential in Multiple Myeloma.'
'At Glenmark, we are committed to expanding access to innovative cancer treatments across Emerging Markets where unmet need and growth potential intersect,' said Christoph Stoller, President – Europe and Emerging Markets, Glenmark Pharmaceuticals. 'The addition of ISB 2001 is a natural evolution of our oncology strategy. With our deep commercial footprint, strong regulatory capabilities, and experience in launching breakthrough assets like BRUKINSA and TEVIMBRA in India, and rights to commercialize QiNHAYO (envafolimab), a PD-L1 checkpoint inhibitor, in Emerging Markets, we are well positioned to deliver impactful treatment option for patients with difficult-to-treat cancers through ISB 2001.'
Headquartered in New York, IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology.
Glenmark Pharmaceuticals is a research‐led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.
On a consolidated basis, Glenmark Pharmaceuticals reported a net profit of Rs 4.65 crore in Q4 March 2025 as against a net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025.
In the cash market, the Nifty 50 index dropped 205.40 points or 0.81% to 25,149.85.
The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, rose 1.24% to 11.82.
Tata Consultancy Services, Glenmark Pharmaceuticals and Infosys were the top traded individual stock futures contracts in the F&O segment of the NSE.
The July 2025 F&O contracts will expire on 31 July 2025.
Anand Rathi Wealth Ltd, Glenmark Pharmaceuticals Ltd, Elecon Engineering Company Ltd, Tata Elxsi Ltd are among the other stocks to see a surge in volumes on NSE today, 11 July 2025.
Netweb Technologies India Ltd recorded volume of 25.61 lakh shares by 14:14 IST on NSE, a 16.14 times surge over two-week average daily volume of 1.59 lakh shares. The stock gained 7.52% to Rs.1,949.00. Volumes stood at 1.46 lakh shares in the last session.
Anand Rathi Wealth Ltd recorded volume of 15.51 lakh shares by 14:14 IST on NSE, a 13.46 times surge over two-week average daily volume of 1.15 lakh shares. The stock gained 3.76% to Rs.2,199.60. Volumes stood at 86029 shares in the last session.
Glenmark Pharmaceuticals Ltd registered volume of 129.6 lakh shares by 14:14 IST on NSE, a 11.28 fold spurt over two-week average daily volume of 11.49 lakh shares. The stock rose 14.41% to Rs.2,178.30. Volumes stood at 34.2 lakh shares in the last session.
Elecon Engineering Company Ltd notched up volume of 50.53 lakh shares by 14:14 IST on NSE, a 8.1 fold spurt over two-week average daily volume of 6.24 lakh shares. The stock slipped 4.84% to Rs.617.30. Volumes stood at 12.77 lakh shares in the last session.
Tata Elxsi Ltd clocked volume of 13.36 lakh shares by 14:14 IST on NSE, a 8.07 times surge over two-week average daily volume of 1.65 lakh shares. The stock lost 1.60% to Rs.6,039.00. Volumes stood at 2.18 lakh shares in the last session.
IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases.
“Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously,” said Roopal Thakkar, M.D., Executive Vice-President, Research and Development and Chief Scientific Officer, AbbVie. “This partnership with IGI reflects our unwavering commitment to advancing novel therapies for patients with multiple myeloma, a disease where significant unmet need remains despite recent progress.”
“ISB 2001 exemplifies the potential of our BEAT® protein platform to generate effective multispecifics™ that may overcome resistance and improve outcomes in hard-to-treat cancers,” said Cyril Konto, M.D., President and CEO of IGI. 'This agreement marks a defining milestone in IGI's scientific journey and reflects our team's deep commitment to delivering meaningful therapies for patients. Our partnership with AbbVie accelerates ISB 2001's path to patients and sharpens our focus on advancing the next generation of BEAT®-enabled assets in oncology.”
Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. Subject to regulatory clearance, IGI will receive an upfront payment of $700 million and is eligible to receive up to $1.225 billion in development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales.
Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1812.1, up 1.6% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.18% on the day, quoting at 25360.65. The Sensex is at 83104.96, down 0.16%. Glenmark Pharmaceuticals Ltd has gained around 14.34% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 3.4% in last one month and is currently quoting at 22204.25, up 0.79% on the day. The volume in the stock stood at 3.99 lakh shares today, compared to the daily average of 10.37 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 1821.7, up 1.76% on the day. Glenmark Pharmaceuticals Ltd is up 35.42% in last one year as compared to a 4.26% jump in NIFTY and a 9.41% jump in the Nifty Pharma index.
The PE of the stock is 28.84 based on TTM earnings ending March 25.